This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Good Pharmacovigilance Practices | |
|---|---|
| Name | Good Pharmacovigilance Practices |
| Jurisdiction | International |
Good Pharmacovigilance Practices are the set of structured processes and standards for monitoring the safety of medicinal products throughout their lifecycle. They align national and regional oversight with industry operations to detect, evaluate, and minimize adverse effects, informing regulatory action and clinical use. These practices interface with international treaties, public health agencies, and pharmaceutical manufacturers to maintain patient safety and therapeutic benefit.
Good Pharmacovigilance Practices sit at the intersection of World Health Organization, European Medicines Agency, United States Food and Drug Administration, Japanese Pharmaceuticals and Medical Devices Agency, and Health Canada activities, integrating guidance from bodies such as International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and conventions like the International Health Regulations (2005). Historically, regulatory impetus followed safety crises involving products associated with the Thalidomide tragedy, prompting legislative action exemplified by laws such as the Food, Drug, and Cosmetic Act and directives from the Council of the European Union. Pharmaceutical manufacturers, academic centres like Johns Hopkins Hospital and research networks including Wellcome Trust consort with national centres such as the MHRA and the Paul Ehrlich Institute to operationalize surveillance.
Regulatory frameworks reflect standards promulgated by European Commission, U.S. Congress, Parliament of Japan, and regional blocs like the African Union and ASEAN. International guidelines issued by ICH, WHO, and the Council for International Organizations of Medical Sciences interact with statutory instruments such as the European Union Directive 2001/83/EC and amendments from bodies like the Committee for Medicinal Products for Human Use. National regulators enforce reporting obligations under statutes such as the Medicines Act (United Kingdom) and codified rules from agencies including the Food and Drug Administration. Global pharmacovigilance networks include collaborations among Pan American Health Organization, GAVI, the Vaccine Alliance, and donor agencies like the Bill & Melinda Gates Foundation.
Core components encompass adverse event reporting systems used by institutes like Centers for Disease Control and Prevention, case processing practices applied in laboratories such as Mayo Clinic, and safety communication channels modeled after initiatives by European Centre for Disease Prevention and Control. Signal management frameworks draw on methodologies developed at academic centres like Harvard Medical School and Oxford University. Risk management plans link to health technology assessment bodies such as National Institute for Health and Care Excellence and payer organizations like Centers for Medicare & Medicaid Services. Pharmacovigilance governance draws on corporate compliance models from multinational firms like Pfizer, Roche, Novartis, Johnson & Johnson, and GlaxoSmithKline.
Signal detection uses databases and tools employed by networks such as VigiBase, scientific methods advanced at Stanford University, and statistical approaches from groups like Cochrane Collaboration. Assessment processes engage expert committees including panels at European Medicines Agency and advisory boards convened by National Institutes of Health. Risk management strategies adopt post-marketing study designs practiced at institutions like Imperial College London and surveillance platforms built by consortia including Sentinel Initiative. Crisis responses coordinate with agencies such as Federal Emergency Management Agency and international mechanisms under World Health Organization leadership.
The Pharmacovigilance System Master File (PSMF) documents organizational structure, processes, and product-specific safety data, following templates referenced by European Medicines Agency guidance and registry practices from Food and Drug Administration. Documentation standards align with quality frameworks used by certification bodies like International Organization for Standardization and archival best practices from institutions such as the Library of Congress. Corporate recordkeeping parallels procedures adopted by pharmaceutical companies including AstraZeneca and contract research organizations like Quintiles.
Quality management integrates principles from ISO 9001 and audit methodologies developed by regulators such as Medicines and Healthcare products Regulatory Agency and inspection regimes used by U.S. Food and Drug Administration and Pharmaceuticals and Medical Devices Agency (Japan). Inspections evaluate compliance with reporting timelines, case processing, and corrective actions; findings inform regulatory actions analogous to enforcement decisions by bodies including European Commission and judicial review in courts like the U.S. Court of Appeals. Third-party auditors and accreditation organizations such as Society of Quality Assurance support continuous improvement.
Training programs for safety professionals draw on curricula from universities such as University of Cambridge, professional societies like International Society of Pharmacovigilance, and certification bodies including Regulatory Affairs Professionals Society. Roles span designated posts within companies (qualified person for pharmacovigilance) and responsibilities for health professionals at hospitals like Cleveland Clinic and public health agencies including Public Health England. Stakeholders encompass regulators, manufacturers, clinicians, patients, and payers represented by entities such as World Bank and non-governmental organizations like Médecins Sans Frontières.